de Zeeuw, Dick2; Akizawa, Tadao2; Audhya, Paul2; Bakris, George L2; Chin, Melanie2; Christ-Schmidt, Heidi2; Goldsberry, Angie2; Houser, Mark2; Krauth, Melissa2; Lambers Heerspink, Hiddo J2; McMurray, John J2; Meyer, Colin J2; Parving, Hans-Henrik1; Remuzzi, Giuseppe2; Toto, Robert D2; Vaziri, Nosratola D2; Wanner, Christoph2; Wittes, Janet2; Wrolstad, Danielle2; Chertow, Glenn M2
1 Endocrinology, Department of, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 unknown
Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.
New England Journal of Medicine, 2013, Vol 369, Issue 26, p. 2492-503